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Author's response to: "Harmful effects form
one puff of shisha-pen vapor:
methodological and interpretational
problems in the risk assessment analysis"
Peter M. J. Bos, Anne S. Kienhuis* and Reinskje Talhout
We thank Dr. Farsalinos and Dr. Baeyens for their com-
ments in their letter to the editor on our publication:
“Potential harmful health effects of inhaling nicotine-free
shisha-pen vapor: a chemical risk assessment of the main
components propylene glycol and glycerol” [1]. Appar-
ently some issues discussed in our publication were not
sufficiently clear and we thank the editor of Tobacco
Induced Diseases for the opportunity to respond to these
comments and clarify the issues raised.
The comments made by Dr. Farsalinos and Dr. Baeyens
focus on four specific issues. Their main concern however,
is about the applicability of our proposal to use the
Margin of Exposure (MOE) approach for risk assessment
of exposure via shisha-pens or electronic cigarettes (e-cig-
arettes). Therefore, we would like to elaborate first on the
application of this approach as a method of risk assess-
ment for exposure to chemicals via smoking and vaping
and why we are of the opinion that, at present, this is the
best method for the present exposure scenario.
The exposure pattern in smoking or vaping is rather
complex. E-cigarettes or shisha-pens may be used during
one or more vaping sessions per day and a session con-
sists of a variable number of puffs. Thus during a day,
exposure is intermittent in two ways, i.e., time intervals
exist between sessions and between puffs within each
session. Since exposure occurs only when a puff is taken,
the daily exposure consists of multiple peak exposures
with irregular time intervals in between. The exposure
assessment is further complicated by the large variation
in the use of e-cigarettes. Based on a market survey of
the use of e-cigarettes in The Netherlands, it has been
estimated that the number of puffs during a day may be
up to 500 (or even larger in individual cases) with a total
duration (i.e., total sum of session duration) of 4 h per
day. The question then raised is how risks can be esti-
mated from such a complex exposure scenario. The
available human limit values for respiratory exposures
are not suitable. Occupational exposure limits (OELs)
are not applicable to the general population and are gen-
erally meant for 8-h exposures while limit values for the
general population (such as Air Quality Guidelines as
published by the WHO) are generally derived for con-
tinuous exposure, i.e., 24 h per day for 7 days per week.
The exposure scenarios for which these limit values are
derived do not match the exposure pattern for vaping.
Hence, the question then is how to proceed if one
wants to assess the health risks from the use of e-
cigarettes or shisha-pens? We believe that the best
option forward is the application of the Margin of
Exposure (MOE) analysis. This approach is commonly
used within different risk assessment frameworks and
has been used before in a risk assessment for exposure
to 1,3-butadiene through smoking [2]. The MOE ap-
proach has also been proposed in risk assessment of
smoking by others (e.g., [3, 4]). A manuscript describing
the application of the MOE within risk assessment of
smoking or vaping in more detail is in preparation.
An MOE is the ratio of a reference point (the PoD),
often taken from an animal study and corresponding to
an exposure that causes a low but measurable response,
and the exposure estimate in humans, taking into ac-
count differences in vaping behaviour (adapted from
[5]). The MOE approach starts with the choice of an ap-
propriate PoD that is derived from an exposure scenario
that closely resembles the exposure scenario under
evaluation and preferably is based on human data.
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In general, only interspecies and inter-individual differ-
ences in susceptibility need to be taken into account if
no adverse effects are observed at the PoD, provided that
the exposure pattern from which the PoD is derived suf-
ficiently resembles the human exposure scenario under
evaluation. Typically, an MOE of minimally a factor of
100 is then required (i.e., a factor of 10 each for interspe-
cies and intraspecies differences) to reach a conclusion
of no concern, i.e., that no adverse health effects are
to be expected. In case a PoD is derived from ad-
equate human data, interspecies differences do not
need to be accounted for and an MOE of 10 might
be concluded sufficient.
If the exposure scenario on which the PoD is based dif-
fers from the regarding human exposure scenario, these
differences need to be bridged by taking them into ac-
count in the evaluation whether an MOE is sufficient to
reach a conclusion of no concern. For instance, if the PoD
is derived from a 13-week animal study a larger MOE is
warranted if human exposure is lifelong. In contrast, a
lower MOE may be considered sufficient if human expos-
ure is for instance only for one hour per day whereas the
PoD is based on a 6-hour exposure per day. By consider-
ing all factors involved in the risk assessment of a human
exposure scenario a minimum value for the MOE may be
determined that is required to reach the conclusion that
no adverse health effects are to be expected.
As to the human exposure scenario of vaping how-
ever, the exposure scenario is so complex that it is
difficult to clearly quantify the differences between
exposure through vaping and for instance a 6-hour
exposure in an animal experiment. This hampers the
assessment of a clear minimum value required for the
MOE. Animal experiments with an exposure pattern
that mimics the exposure during the use of an e-
cigarette are not available. Furthermore, the question
would arise what the appropriate exposure pattern in
the animal experiment would be, considering the
large inter-individual variation of e-cigarette use. The
more intensive the vaping behaviour, the higher the MOE
should be to reach a conclusion of no concern. The best
way forward then is to calculate the MOE, to list the
factors to be accounted for by the MOE, to quantify these
factors where possible and to include the remaining not-
quantifiable factors in the evaluation of the MOE by
expert judgement. It is noted that the minimal value re-
quired for the MOE depends on the information available
and on the exposure characteristics and thus will be differ-
ent for different scenarios.
In general, the interval in between two puffs will be
sufficiently long such that the alveolar concentration will
have decreased to zero before the next puff. Therefore,
as a first approach the exposure from a single puff can
be estimated and compared with the most appropriate
PoD available. The exposure assessment may either be
an estimate of the pulmonary or alveolar concentration
(if local effects are the endpoint of concern) or of the
absorbed dose (in case systemic effects are of interest).
The exposure estimate for a single puff can then easily
be extrapolated to more intensive users. In case of local
effects, such as respiratory tract irritation, the total dur-
ation of the daily exposure can be estimated from the
total duration of the daily vaping sessions combined with
the puff frequency during these sessions. Combined with
the exposure concentration estimated for a single puff
this provides an estimate of the daily exposure that can
be used for the calculation of the MOE. Any remaining
differences can be considered in the evaluation of the
MOE, including the fact that exposure is actually not con-
tinuous but to peaks with intermediate zero alveolar con-
centrations. As to systemic exposure, the dose taken up
from one puff can easily be multiplied by the total daily
number of puffs to estimate the total daily systemic dose.
However, it should then be kept in mind that the rate at
which a substance enters the systemic circulation is also
of importance. This aspect might be taken into account by
additionally including the puff frequency in the evaluation.
In summary, the risk assessment of the use of e-
cigarettes or shisha-pens is complex but the MOE
approach can be used to obtain a first pragmatic risk es-
timate, and to our opinion is at present the best option
despite the uncertainties involved. The exposure from a
single puff can be estimated and extrapolated towards
more intensive use, depending on whether one wants to
assess the health risks for e.g., a light, mediate or heavy
user of e-cigarettes or, as in the present case, of shisha-
pens. Therefore, the focus of our paper was on single-
puff exposure that could easily be extrapolated to
another vaping behaviour of choice rather than focusing
on possible risks in one specific well-described vaping
scenario. Apparently, our paper was not very clear on
this point. Obviously, a single-puff exposure will be in-
sufficient to induce adverse health effects.
Having said that, we come back to the four specific is-
sues raised by Dr. Farsalinos and Dr. Baeyens. The first
point raised regards the risk assessment for propylene
glycol. Although the purity of the propylene glycol used
by Wieslander et al. [6] is indeed unknown even indus-
trial grade propylene glycol may have a purity of more
than 99.5 %1. Further, it is well-known that propylene
glycol has irritating properties, due to its dehydrogenat-
ing properties [7]. It can therefore be safely assumed that
the findings reported by Wieslander et al. [6] are in-
duced by propylene glycol and that any impurities
present in the aerosol mist, will have had a minor contri-
bution, if any.
We estimated that the alveolar concentration of propyl-
ene glycol after one puff may be as high as approximately
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500 mg/m3, comparable to the concentrations reported by
Wieslander et al. [6] that induced upper airway irritation.
The alveolar concentration is also significantly higher than
the lowest concentration of 160 mg/m3 tested in a 13-
week rat study, which was an effect level for nasal haem-
orrhage [8]. In case of a lifetime human exposure scenario
of 6 h per day, the minimum value required for an MOE
would be at least about 200 (i.e., 10 for interspecies, 10
for interindividual differences in susceptibility, 2 for
subchronic to lifetime extrapolation), meaning that a
safe exposure concentration for a daily 6-h exposure
for humans would be less than 1 mg/m3. To which ex-
tent a shorter daily exposure duration then balances a
much higher exposure concentration cannot be verified
due to insufficient data. However, the estimated alveo-
lar concentration after one puff in itself is sufficiently
high to potentially induce adverse effects on the re-
spiratory tract. The effects reported both by Wieslander
et al. [6] and by Suber et al. [8] are clearly unwanted
from a risk perspective point of view and are therefore
considered as adverse. It can therefore be safely con-
cluded that the heavier the daily use of a shisha-pen the
higher the possibility that adverse health effects on the
upper airways will occur, although the minimum number
of daily puffs at which effects can be expected cannot be
assessed due to insufficient data. This minimum number
will also differ between individuals, since individuals show
differences in susceptibility towards hazardous chemicals.
Furthermore, in the light of the present discussion it is
interesting that at the FAQ website of The members of
the Propylene Oxide/Propylene Glycol sector group of
CEFIC2 one of the questions is whether the use of pro-
pylene glycol in e-cigarettes is safe. The answer states
that “The producers of propylene glycol and members of
Cefic’s PO/PG sector group do not support the use of pro-
pylene glycol in electronic cigarettes, nor in artificial (the-
atrical) fogs due to possible effects on the eye, nose, throat,
and respiratory tract membranes as well as the absence of
information on potential long term effects from prolonged
inhalation of (fine) droplets of propylene glycol.”
In summary, the main point that we would like to
stress is that in principle the alveolar concentration fol-
lowing one puff is sufficiently high to potentially induce
adverse effects on the upper respiratory tract. Whether
these effects will occur obviously depends on the num-
ber of puffs, the puff frequency and/or on the total dur-
ation of daily exposure. It cannot be ruled out that even
brief peak exposures to such high concentrations may
induce adverse effects provided that the number of
peaks is sufficiently high. The effects reported by Wies-
lander et al. [6] in humans exposed for only one minute
might indicate that for propylene glycol the use of
shisha-pens might not need to be much more intensive
before adverse effects can be expected. The fact that Dr.
Farsalinos and Dr. Baeyens state that “throat irritation is
commonly called “throat hit” by smokers and vapers” in-
dicates that these effects are known among vapers. This
is further underpinned by their remark that complaints
including dry/irritated mouth and throat occurred
among e-cigarette users.
The same issues as discussed for propylene glycol also
hold for the risk assessment for glycerol, which is the
second point raised. Also for glycerol, the estimated al-
veolar concentration is high (approximately 400 mg/m3)
and of the same order of magnitude as the concentra-
tions that induced adverse effects on the respiratory
tract in rats exposed for 6 h/day for 13 weeks [9]. As
mentioned before in the response but also already in our
paper [1], we acknowledge that a 6-h daily exposure sig-
nificantly differs from the brief peak exposures following
each puff from a shisha-pen. But, similarly as for propyl-
ene glycol, the heavier the use of a shisha-pen the higher
the possibility for adverse effects on the respiratory tract
due to glycerol exposure.
As to the third point, we agree with Dr. Farsalinos and
Dr. Baeyens that the statement in our manuscript that
the effects reported by Suber et al. [8] are irreversible, is
inaccurate. Although no recovery group was included in
the study it can be fairly concluded that the effects re-
ported (including the nasal haemorrhages, the elevation
in the number of goblet cells and the elevated mucin
production) will be reversible. However, we would like
to emphasize that whether an effect is reversible or not
is only of importance in case of cessation of exposure. In
case of lifelong exposure the fact that an effect is (ir)re-
versible does not alter the conclusions of a risk assess-
ment itself.
As a last point, Dr. Farsalinos and Dr. Baeyens plead
that the evaluation of the use of e-cigarettes should always
be in the context of smoking since e-cigarettes are mainly
used as an alternative to smoking. However, e-cigarette
use is subject of discussion of opposite camps and we be-
lieve the discussions are best helped forward if potential
health risks of e-cigarette use are judged on their own
merits. As to the shisha-pen, which was the main focus of
our paper, there was more reason to discuss possible risks
from shisha-pen use in itself, since the marketing of
shisha-pens also aims at children or teen-agers.
We approached the use of shisha-pens from the per-
spective of risk assessment, irrespective of the experi-
ences and opinions of vapers. This includes that effects,
causing a diminished functioning of a tissue or organ or
a decreased well-being, are considered as unwanted and
therefore adverse. Within that context irritation of the
respiratory tract is considered to be an adverse health ef-
fect. We believe it is the task of a risk assessor to clearly
point out health risks involved in exposure to hazardous
chemicals, thereby including actions leading to such an
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exposure. If a person is willing to take such a risk it is
an individual’s choice.
Considering the increasing use of e-cigarettes and the
lack of insight in the actual risks involved in their use, it
is of importance to develop a method to assess these
risks. Applicable human limit values are not available.
Therefore, we believe that the MOE approach is the best
option forward. However, at the same time we acknow-
ledge that the data that are actually needed for this ap-
proach are not available yet. This holds both for an
appropriate exposure assessment as for the necessary
toxicological information needed to address the expos-
ure scenario of smoking or vaping. The MOE can be
used as a first pragmatic approach and by application it
will reveal the uncertainties involved and thereby make
clear what kind of data is needed to adequately address
human risk assessment from smoking or vaping. We
hope that future research on e-cigarettes will also focus
on filling in data gaps to improve the assessment of
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